Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Low-dose PW-2101 fails to meet primary endpoint in pivotal hypertension study

Dec. 7, 2004

EP-2306 and EP-2302 effectively inhibit LDL oxidation, possible application in atherosclerosis

Dec. 7, 2004

Citrus bioflavonoid naringin and lovastatin show comparable hypocholesterolemic effects in vivo

Dec. 7, 2004

Tumor necrosis factor inhibitor may attenuate postmyocardial infarction ventricular remodeling

Dec. 3, 2004

Iroxanadine shows promise for cardiovascular disease in mouse study

Dec. 3, 2004

Diovan approved in Sweden to treat high-risk heart attack patients

Dec. 3, 2004

Cilnidipine for the treatment of arrhythmia

Dec. 2, 2004

Myogen completes two pivotal clinical trials on enoximone in CHF

Dec. 2, 2004

Cardiome selects oral controlled-release formulation of RSD-1235

Dec. 1, 2004

Atacand approved in Europe for treatment of chronic heart failure

Nov. 30, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...